Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer
Attard CL, Brown S, Alloul K, Moore MJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.3747/co.21.1327

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Cost-Benefit Analysis; Pancreatic Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols

AccessionNumber
22014008668

Date bibliographic record published
04/04/2014